{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:22:54Z","timestamp":1783635774941,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.carrev.2019.10.007","type":"journal-article","created":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T11:53:12Z","timestamp":1571399592000},"page":"785-789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["MAPT (Mono Antiplatelet Therapy) as Regular Regimen After COBRA PzF\u2122 NanoCoated Coronary Stent (NCS) Implantation"],"prefix":"10.1016","volume":"21","author":[{"given":"Luc","family":"Maillard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Vochelet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Peycher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anis","family":"Ayari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Barra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Bill\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"S\u00e9villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Tavildari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.carrev.2019.10.007_bb0005","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Schomig","year":"1996","journal-title":"N Engl J Med."},{"key":"10.1016\/j.carrev.2019.10.007_bb0010","doi-asserted-by":"crossref","unstructured":"Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol. 2007;50(14):1299-304. doi:S0735-1097(07)02206-1 [pii] https:\/\/doi.org\/10.1016\/j.jacc.2007.06.029.","DOI":"10.1016\/j.jacc.2007.06.029"},{"key":"10.1016\/j.carrev.2019.10.007_bb0015","doi-asserted-by":"crossref","unstructured":"Valgimigli M. The ESC DAPT guidelines 2017. Eur Heart J. 2018;39(3):187\u20138. doi:4804119 [pii] https:\/\/doi.org\/10.1093\/eurheartj\/ehx768 [doi].","DOI":"10.1093\/eurheartj\/ehx768"},{"key":"10.1016\/j.carrev.2019.10.007_bb0020","doi-asserted-by":"crossref","unstructured":"Bittl JA, Baber U, Bradley SM, Wijeysundera DN. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1116\u201339. doi:S0735-1097(16)01698-3 [pii] https:\/\/doi.org\/10.1016\/j.jacc.2016.03.512 [doi].","DOI":"10.1016\/j.jacc.2016.03.512"},{"issue":"21","key":"10.1016\/j.carrev.2019.10.007_bb0025","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.carrev.2019.10.007_bb0030","doi-asserted-by":"crossref","unstructured":"Capodanno D, Tamburino C. Properties and clinical development of a novel coating technology: the poly[bis(trifluoroethoxy)phosphazene]. Recent Pat Drug Deliv Formul. 2010;4(1):18\u201322. doi:Abstract 11 for E.Pub [pii].","DOI":"10.2174\/187221110789957264"},{"key":"10.1016\/j.carrev.2019.10.007_bb0035","doi-asserted-by":"crossref","unstructured":"Koppara T, Sakakura K, Pacheco E, Cheng Q, Zhao X, Acampado E et al. Preclinical evaluation of a novel polyphosphazene surface modified stent. Int J Cardiol. 2016;222:217\u201325. doi:S0167-5273(16)31576-5 [pii] https:\/\/doi.org\/10.1016\/j.ijcard.2016.07.181 [doi].","DOI":"10.1016\/j.ijcard.2016.07.181"},{"key":"10.1016\/j.carrev.2019.10.007_bb0040","doi-asserted-by":"crossref","unstructured":"Maillard L, Tavildari A, Barra N, Bille J, Joly P, Peycher P et al. Immediate and 1-year follow-up with the novel nanosurface modified COBRA PzF stent. Arch Cardiovasc Dis. 2017;110(12):682\u20138. doi:S1875\u20132136(17)30183\u20133 [pii] https:\/\/doi.org\/10.1016\/j.acvd.2017.04.010 [doi].","DOI":"10.1016\/j.acvd.2017.04.010"},{"key":"10.1016\/j.carrev.2019.10.007_bb0045","doi-asserted-by":"crossref","unstructured":"Cutlip DE, Garratt KN, Novack V, Barakat M, Meraj P, Maillard L et al. 9-Month clinical and angiographic outcomes of the COBRA polyzene-F NanoCoated Coronary stent system. JACC Cardiovasc Interv. 2017;10(2):160\u20137. doi:S1936-8798(16)31910-0 [pii] https:\/\/doi.org\/10.1016\/j.jcin.2016.10.037 [doi].","DOI":"10.1016\/j.jcin.2016.10.037"},{"key":"10.1016\/j.carrev.2019.10.007_bb0050","doi-asserted-by":"crossref","unstructured":"Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344\u201351. doi:115\/17\/2344 [pii] https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.685313.","DOI":"10.1161\/CIRCULATIONAHA.106.685313"},{"issue":"23","key":"10.1016\/j.carrev.2019.10.007_bb0055","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1056\/NEJMoa1610227","article-title":"Everolimus-eluting stents or bypass surgery for left main coronary artery disease","volume":"375","author":"Stone","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.carrev.2019.10.007_bb0060","doi-asserted-by":"crossref","unstructured":"Schatz RA, Goldberg S, Leon M, Baim D, Hirshfeld J, Cleman M et al. Clinical experience with the Palmaz-Schatz coronary stent. J Am Coll Cardiol. 1991;17(6 Suppl B):155B-9B. doi:0735-1097(91)90952-6 [pii].","DOI":"10.1016\/0735-1097(91)90952-6"},{"issue":"7","key":"10.1016\/j.carrev.2019.10.007_bb0065","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/01.CIR.94.7.1519","article-title":"Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-Day clinical outcome of the French Multicenter Registry","volume":"94","author":"Karrillon","year":"1996","journal-title":"Circulation."},{"issue":"23","key":"10.1016\/j.carrev.2019.10.007_bb0070","first-page":"1665","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting","volume":"339","author":"Leon","year":"1998","journal-title":"Stent anticoagulation restenosis study investigators. N Engl J Med."},{"issue":"6","key":"10.1016\/j.carrev.2019.10.007_bb0075","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1161\/01.CIR.91.6.1676","article-title":"Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance","volume":"91","author":"Colombo","year":"1995","journal-title":"Circulation."},{"issue":"1","key":"10.1016\/j.carrev.2019.10.007_bb0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1540-8183.2009.00516.x","article-title":"Radial artery access as an emerging factor for decreasing mortality in cardiovascular interventions","volume":"23","author":"Cevik","year":"2010","journal-title":"J Interv Cardiol."},{"issue":"2","key":"10.1016\/j.carrev.2019.10.007_bb0085","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/01.CIR.95.2.438","article-title":"Stent endothelialization. Time course, impact of local catheter delivery, feasibility of recombinant protein administration, and response to cytokine expedition","volume":"95","author":"Van Belle","year":"1997","journal-title":"Circulation."},{"issue":"2","key":"10.1016\/j.carrev.2019.10.007_bb0090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/heart.89.2.133","article-title":"Drug eluting stents: are human and animal studies comparable?","volume":"89","author":"Virmani","year":"2003","journal-title":"Heart."},{"issue":"23","key":"10.1016\/j.carrev.2019.10.007_bb0095","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1161\/01.CIR.103.23.2816","article-title":"Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial","volume":"103","author":"Kastrati","year":"2001","journal-title":"Circulation."},{"key":"10.1016\/j.carrev.2019.10.007_bb0100","doi-asserted-by":"crossref","unstructured":"Grines CL, Bonow RO, Casey DE, Jr., Gardner TJ, Lockhart PB, Moliterno DJ et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007;115(6):813\u20138. doi:CIRCULATIONAHA.106.180944 [pii] https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.180944.","DOI":"10.1161\/CIRCULATIONAHA.106.180944"},{"key":"10.1016\/j.carrev.2019.10.007_bb0105","doi-asserted-by":"crossref","unstructured":"Avezum A, Makdisse M, Spencer F, Gore JM, Fox KA, Montalescot G et al. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J. 2005;149(1):67\u201373. doi:S0002870304003953 [pii] https:\/\/doi.org\/10.1016\/j.ahj.2004.06.003.","DOI":"10.1016\/j.ahj.2004.06.003"},{"key":"10.1016\/j.carrev.2019.10.007_bb0110","doi-asserted-by":"crossref","unstructured":"Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370(9591):937\u201348. doi:S0140-6736(07)61444-5 [pii] https:\/\/doi.org\/10.1016\/S0140-6736(07)61444-5 [doi].","DOI":"10.1016\/S0140-6736(07)61444-5"},{"issue":"10","key":"10.1016\/j.carrev.2019.10.007_bb0115","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa066633","article-title":"A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents","volume":"356","author":"Spaulding","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1016\/j.carrev.2019.10.007_bb0120","doi-asserted-by":"crossref","unstructured":"Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007;27(7):1500\u201310. doi:ATVBAHA.107.144220 [pii] https:\/\/doi.org\/10.1161\/ATVBAHA.107.144220.","DOI":"10.1161\/ATVBAHA.107.144220"},{"issue":"5","key":"10.1016\/j.carrev.2019.10.007_bb0125","first-page":"567","article-title":"Polymer coatings and delayed arterial healing following drug-eluting stent implantation","volume":"57","author":"Byrne","year":"2009","journal-title":"Minerva Cardioangiol."},{"issue":"8","key":"10.1016\/j.carrev.2019.10.007_bb0130","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJM199408253310801","article-title":"A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease","volume":"331","author":"Serruys","year":"1994","journal-title":"Benestent Study Group. N Engl J Med."},{"issue":"7","key":"10.1016\/j.carrev.2019.10.007_bb0135","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.carrev.2019.10.007_bb0140","doi-asserted-by":"crossref","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001\u201315. doi:NEJMoa0706482 [pii] https:\/\/doi.org\/10.1056\/NEJMoa0706482.","DOI":"10.1056\/NEJMoa0706482"},{"key":"10.1016\/j.carrev.2019.10.007_bb0145","doi-asserted-by":"crossref","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357. doi:NEJMoa0904327 [pii] https:\/\/doi.org\/10.1056\/NEJMoa0904327.","DOI":"10.1056\/NEJMoa0904327"},{"key":"10.1016\/j.carrev.2019.10.007_bb0150","doi-asserted-by":"crossref","unstructured":"Jinnouchi H, Mori H, Cheng Q, Kutyna M, Torii S, Sakamoto A et al. Thromboresistance and functional healing in the COBRA PzF Stent versus competitor DES: implications for dual anti-platelet therapy. EuroIntervention. 2018. doi:EIJ-D-18-00740 [pii] https:\/\/doi.org\/10.4244\/EIJ-D-18-00740.","DOI":"10.4244\/EIJ-D-18-00740"},{"key":"10.1016\/j.carrev.2019.10.007_bb0155","doi-asserted-by":"crossref","unstructured":"Urban P, Abizaid A, Banning A, Bartorelli AL, Baux AC, Dzavik V et al. Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population: a report from the e-SELECT (Multi-Center Post-Market Surveillance) registry. J Am Coll Cardiol. 2011;57(13):1445\u201354. doi:S0735\u20131097(11)00187\u20132 [pii] https:\/\/doi.org\/10.1016\/j.jacc.2010.11.028.","DOI":"10.1016\/j.jacc.2010.11.028"},{"key":"10.1016\/j.carrev.2019.10.007_bb0160","doi-asserted-by":"crossref","unstructured":"Cuisset T, Frere C, Poyet R, Quilici J, Gaborit B, Bali L et al. Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. Arch Cardiovasc Dis. 2010;103(1):39\u201345. doi:S1875-2136(09)00325-8 [pii] https:\/\/doi.org\/10.1016\/j.acvd.2009.11.004.","DOI":"10.1016\/j.acvd.2009.11.004"},{"key":"10.1016\/j.carrev.2019.10.007_bb0165","doi-asserted-by":"crossref","unstructured":"Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56(12):919\u201333. doi:S0735-1097(10)02473-3 [pii] https:\/\/doi.org\/10.1016\/j.jacc.2010.04.047.","DOI":"10.1016\/j.jacc.2010.04.047"},{"key":"10.1016\/j.carrev.2019.10.007_bb0170","doi-asserted-by":"crossref","unstructured":"Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrie D et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet. 2018;391(10115):41\u201350. doi:S0140-6736(17)32713-7 [pii] https:\/\/doi.org\/10.1016\/S0140-6736(17)32713-7 [doi].","DOI":"10.1016\/S0140-6736(17)32713-7"},{"key":"10.1016\/j.carrev.2019.10.007_bb0175","doi-asserted-by":"crossref","unstructured":"Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107\u201315. doi:S0140-6736(12)62177-1 [pii] https:\/\/doi.org\/10.1016\/S0140-6736(12)62177-1 [doi].","DOI":"10.1016\/S0140-6736(12)62177-1"},{"issue":"25","key":"10.1016\/j.carrev.2019.10.007_bb0180","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.carrev.2019.10.007_bb0185","doi-asserted-by":"crossref","unstructured":"Morice MC, Talwar S, Gaemperli O, Richardt G, Eberli F, Meredith I et al. Drug-coated versus bare-metal stents for elderly patients: A predefined sub-study of the LEADERS FREE trial. Int J Cardiol. 2017;243:110\u20135. doi:S0167-5273(17)30829-X [pii] https:\/\/doi.org\/10.1016\/j.ijcard.2017.04.079.","DOI":"10.1016\/j.ijcard.2017.04.079"},{"issue":"14","key":"10.1016\/j.carrev.2019.10.007_bb0190","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.carrev.2019.10.007_bb0195","doi-asserted-by":"crossref","unstructured":"Vranckx P, Valgimigli M, Juni P, Hamm C, Steg PG, Heg D et al. Ticagrelor plus aspirin for 1\u202fmonth, followed by ticagrelor monotherapy for 23\u202fmonths vs aspirin plus clopidogrel or ticagrelor for 12\u202fmonths, followed by aspirin monotherapy for 12\u202fmonths after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392(10151):940\u20139. doi:S0140-6736(18)31858-0 [pii] https:\/\/doi.org\/10.1016\/S0140-6736(18)31858-0.","DOI":"10.1016\/S0140-6736(18)31858-0"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838919306566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838919306566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:17:12Z","timestamp":1761560232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838919306566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1553838919306566"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2019.10.007","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MAPT (Mono Antiplatelet Therapy) as Regular Regimen After COBRA PzF\u2122 NanoCoated Coronary Stent (NCS) Implantation","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2019.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}